



V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 9 6 – 8 0 3
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva lISPOR TASK FORCE REPORTS
Modeling Good Research Practices—Overview: A Report of the
ISPOR-SMDM Modeling Good Research Practices Task Force-1
J. Jaime Caro, MDCM, FRCPC, FACP1,2,*, Andrew H. Briggs, Dphil3, Uwe Siebert, MD, MPH, MSc, ScD4,5,
Karen M. Kuntz, ScD6, on Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force
1Faculty of Medicine, McGill University, QC, Montreal, Canada; 2United BioSource Corporation, Lexington, MA, USA; 3Health Economics & Health Technology
Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; 4UMIT – University for Health Sciences, Medical Informatics and
Technology, Hall i.T., and Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Austria; 5School of Public Health and Medical School, Harvard







CModels—mathematical frameworks that facilitate estimation of the
consequences of health care decisions—have become essential tools
for health technology assessment. Evolution of the methods since the
first ISPOR Modeling Task Force reported in 2003 has led to a new Task
Force, jointly convened with the Society for Medical Decision Making,
and this series of seven articles presents the updated recommenda-
tions for best practices in conceptualizing models; implementing state-
transition approaches, discrete event simulations, or dynamic trans-













ttp://dx.doi.org/10.1016/j.jval.2012.06.012eporting models transparently. This overview article introduces the
ork of the Task Force, provides all the recommendations, and dis-
usses some quandaries that require further elucidation. The audience
or these articles includes those who build models, stakeholders who
tilize their results, and, indeed, anyone concerned with the use of
odels to support decision making.
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opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The use of models to support scientific endeavor is ubiquitous.
Models are essentially communication tools that allow the com-
plexity of a given system to be reduced to its essential elements. As
such, models represent a simplification of reality and modeling is
necessarily a reductionist methodology. This series of articles
[1–6] relates to the application of modeling techniques to the area
of health care decision making. This can include not only clinical
decision models, designed to assist individual clinicians and their
patients with decisions regarding their care, but also policy deci-
sion models, designed to more broadly evaluate whether particu-
lar health care technologies should be provided within the context
of an organized health care system. These latter types of models
are characterized by the need to explicitly include a budget con-
straint and therefore necessarily include both resource conse-
quences and health outcomes in a health economic evaluation
framework. Therefore, while these articles focus on modeling,
drawing broadly on general methods, and apply beyond health
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* Address correspondence to: J. Jaime Caro, United BioSource Corp
E-mail: jaime.caro@mcgill.ca.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.economic assessment, the series necessarily touches on many as-
pects pertaining to economic evaluation.
Although the use of models to inform policy decision about the
use of health technologies has been increasing [7], there remain
strong concerns with their credibility [8,9]—a concern that is not
unique to our field [10–12]. To help allay these concerns, several
guidelines for good practices in modeling have been issued [13]. In
000, the International Society for Pharmacoeconomics and Out-
omes Research Task Force on Good Research Practices in Model-
ng Studies was created and after an extensive process of consul-
ation, it issued its report in 2003. This report defined a model and
ts purpose, laid out the approach to evaluating a model, and de-
cribed the Task Force’s consensus regarding the attributes that
haracterize a good model, in terms of structure, data, and valida-
ion [14].
In the intervening years, the range of modeling techniques for
edical and economic decision modeling has advanced substan-
ially [15,16], as modelers in our discipline have become acquainted
ith more sophisticated modeling techniques. The relative simplic-
ty of cohort-based models is still an attraction for many modelers
de modeling activities among their professional practices and in
ults. Some members of the Task Force own intellectual property
rted by citations to articles authored by Task Force members. The
the deliberations or the content of these articles.
ion, 430 Bedford Street, Lexington, MA 02420.
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decision problem demands taking extensive history into account and
individual-level microsimulation methods are required [17]. One ap-
proach to implementing individual-level simulations is an adapta-
tion of methods borrowed from engineering and operations re-
search, which frames the problem in terms of the states individuals
can be in and the events that can happen to them and their conse-these guidelines be updated in due course.present additional challenges and require somewhat different ap-
proaches to modeling. Infectious disease modeling is a further ap-
proach that can handle interaction between individuals, and this
dynamic form of modeling has also developed its own set of chal-
lenges and techniques [20]. The methods for simultaneously han-
dling multiple parameters of a model and addressing uncertainty
have also progressed significantly, and the approach to validation ofquences [18,19]. These individual-level and stochastic techniques models has received increasing attention.
Background to the Task Force
To ensure that the guidelines for good practices in modeling
remain current, effective, and helpful, ISPOR judged it necessary
to update them to accord with the newer methods being used in
practice. As a result, a new Good Research Practices in Modeling
Task Force was constituted to build on the excellent work done
by the initial one from 2000 to 2003. To bring to bear the broadest
expertise in this area, the Society for Medical Decision Making
(SMDM) was invited to join the effort. The Task Force was asked
to provide guidelines for designing the approach, selecting a
technique, implementing and validating the model, parameter-
izing the inputs and assessing uncertainty, and using the result-
ing tool to inform decision making.
Early in 2010, the ISPOR and SMDM boards appointed the co-
chairs and consented to the proposed members of the Task
Force. The Task Force convened expert developers and experi-
enced users of models from academia, industry, and govern-
ment, with representation from many countries. Given the
breadth of the field at this point, a decision was made to divide
the topic into six components and leads were appointed for each
working group. Three of these topics covered the aspects felt to
be general to all models in our field: conceptualization of a
model, estimation of model parameters and handling of uncer-
tainty, and validation of models and concerns for transparency.
The other three dealt with specific techniques in common use:
state-transition modeling, discrete event simulation, and dy-
namic transmission models. While there are undoubtedly topics
of interest that are not addressed in these six articles, it was felt
that these reports would cover the major areas that are at a stage
of development appropriate for issuing guidelines.
The Task Force held its first meeting via teleconference on
May 7, 2010, and hosted information sessions during 2010 at the
ISPOR 15th Annual International Meeting in Atlanta, GA, at the
32nd Annual Meeting of the Society for Medical Decision Making
in Toronto, ON, and at the ISPOR 13th Annual European Congress
in Prague. Over numerous teleconferences, and occasional in-
person meetings, the working groups produced draft reports for
each section. Although the groups referred to the literature fre-
quently, there was no systematic attempt to review it. Although
substantiated as much as possible, the recommendations that
emerged represent the opinions of the experts in the Task Force.
These were not forced to consensus, and had substantial differ-
ences of opinion remained, they would have been documented
as such. The draft recommendations were discussed by the Task
Force as a whole in a meeting held in Boston in March 2011 and
subsequently edited and circulated to the Task Force members
in the form of a survey where each one was asked to agree or
disagree with a recommendation, and if the latter, to provide the
reason(s). Each group received the results of the survey and en-
deavored to address all rejections. In the end, there were no
dissenting positions. The final drafts of the articles were posted
on the ISPOR and SMDM Web sites for comment by the general
membership of the societies.
A second group of experts—again, with broad representa-
tion of modelers and users of models—was invited to formally
review the articles. Their comments were addressed by each
working group, and revised drafts of each article were circu-
lated to the Task Force as a whole. After receiving any addi-
tional comments and considering any further revisions, the
final version of each article was prepared. (A copy of the orig-
inal draft of this article, as well as the reviewer comments and
author responses, is available at the ISPOR Web site: http://
www.ispor.org/workpaper/Modeling-Good-Research-Practices-
Overview.asp.) A summary of these articles was presented at a
plenary session at the ISPOR 16th Annual International Meet-
ing in Baltimore, MD, in May 2011, and again at the 33rd An-
nual Meeting of the Society for Medical Decision Making in
Chicago, IL, in October 2011. These articles are jointly pub-
lished in the Societies’ respective journals, Value in Health and
Medical Decision Making.The audience for this set of articles encompasses both the re-
searchers who develop models and those who use models to in-
form decisions. Investigators charged with reviewing others’ mod-
els should find the guidelines helpful in their assessments. Even
those affected by the decisions informed by models and those who
report on the results of modeling analyses should find these rec-
ommendations useful.
It is important to note, however, that these articles are not
intended as primers on their subjects. General textbooks and tu-
torial articles covering these techniques exist [21–25], and specific
publications that address the methods are cited throughout. By
the same token, these articles are not methodological treatises
that address every aspect of a particular topic. Instead, they pro-
pose a set of best practices for modeling. They focus on the types of
models and approaches taken today, not on nascent ones or even
on those whose use is currently being debated (e.g., model aver-
aging [26]). Further development of the methods will require thatAlthough it may not be possible to follow the entire set of rec-
ommendations in every modeling exercise, these do represent
what the Task Force felt to be the best practices for modeling today
and each recommendation should be given serious consideration.
Nevertheless, the guidelines are not intended for use as a checklist
to be followed unthinkingly. We encourage modelers who believe
that they should not, or cannot, follow a particular recommenda-
tion to document this divergence, its rationale and likely conse-
quences for their model, and its results and the inferences that
will guide decision makers.
This overview article presents the process and methods of
the Task Force and gives the reader an orientation to the con-
tents of each of the detailed articles. It also provides all the
recommendations of the Task Force, but without their detailed
rationales and caveats. General quandaries and gaps in knowl-
edge not covered in the other articles are addressed in the final
section, along with some thoughts on developments in this
area.
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A reader wishing to have a comprehensive view of the recommen-
dations should approach the articles in order: first the one dealing
with conceptualizing a model, then the three articles addressing
specific techniques, followed by the article on parameter estima-
tion and uncertainty, and concluding with the one on transpar-
ency and validation. If the detailed explanations are not required,
then this overview article can be consulted for the list of recom-
mendations.
The articles generally follow the same structure. After an in-
troduction, the key concepts and definitions pertinent to each
topic are laid out, followed by presentation of the recommenda-
tions and their rationale. Each group was given leeway, however,
to approach its subject in the way it felt was best. The conceptu-
alization article begins by defining the term “model.” In the sense
used by the Task Force, a model is a mathematical framework rep-
resenting some aspects of reality at a sufficient level of detail to
inform a clinical or policy decision [1]. The article then outlines the
modeling process that begins with carefully examining the deci-
sion problem and laying out the elements required. Along the way,
the designers will make many decisions. They will select what
aspects of reality to include and to what extent they are detailed,
driven by who their audience is (the “perspective”) and the imper-
ative to sufficiently reflect reality. They will choose the time span
the model is to cover (“time horizon”), its target population(s),
which interventions to consider, how to structure the model,
which outcomes to report, and many other features. The article
underscores that conceptualizing the model should precede ex-
amination of the available data to avoid designing a model that
lacks key components and, thus, poorly represents the decision
problem. It also emphasizes the importance of understanding the
policy context and broad consultation with experts. This article
concludes with guidance on choosing a technique for implement-
ing the model.
The three articles on modeling techniques begin with defini-
tion of the technique and details of the key elements that charac-
terize it. Indications on when to use the technique are given, and
structuring of the model using that technique is described. All
three conclude with suggestions on how to communicate that
type of model. The state-transition article also deals briefly with
decision trees, a simpler technique that is sometimes adequate for
the decision problem at hand. The article on discrete event simu-
lation spends somewhat more effort orienting readers to the tech-
nique, given that today it is less commonly used in medical con-
texts. The article on dynamic transition models devotes more
space to the parameters involved because these are a crucial and
prominent component of this type of model.
In the article regarding parameter estimation and uncertainty,
significant effort is made to bring order to the unruly terminology
pertaining to uncertainty (though, undoubtedly, practitioners will
still want to cling to their favorite terms). The connection between
estimation and subsequent uncertainty analyses is emphasized
and the choices of distributions are described. Calibration meth-
ods and structural uncertainty are briefly addressed, and the arti-
cle concludes with extensive guidance on the reporting of uncer-
tainty.
The final article in the series deals with the twin aspects of
transparency and validation. It begins with the thorny topic of
trusting the results of a model enough to allow them to guide a
decision and how this can be achieved. It discusses both technical
and nontechnical documentation of a model, designed to achieve
the required transparency, emphasizing that it is inappropriate to
require that a model be understandable at full depth by someone
without the necessary technical know-how. The types of valida-
tion, their necessity and sufficiency, and interpretation are then
addressed in detail.Best Practices
II. Conceptualizing the model
II-1 The modeling team should consult widely with subject ex-
perts and stakeholders to assure that the model represents
disease processes appropriately and adequately addresses the
decision problem.
II-2 A clear, written statement of the decision problem, model-
ing objective, and scope of the model should be developed. This
should include: the spectrum of disease considered, perspec-
tive of the analysis, target population, alternative interven-
tions, health and other outcomes, and time horizon.
II-2a The scope and structure of the model should be con-
sistent with, and adequate to address, the decision prob-
lem/objective and the policy context.
II-2b The perspective of the analysis should be stated and
defined. Outcomes modeled in the analysis should be con-
sistent with the stated perspective. Analyses which take a
perspective narrower than the societal perspective should
report which outcomes are included and which are ex-
cluded.
II-2c The target population should be defined in terms of
geography, patient characteristics (including co-morbid
conditions), and disease stage, each of which should be ap-
propriate to the decision problem.
II-2d Health outcomes modeled in the analysis, which may
be measured as events, cases of disease, deaths, quality-
adjusted life-years, disability-adjusted life-years, or other
measures important to decision makers and stakeholders,
should be directly relevant to the question being asked.
II-2e Interventions or strategies modeled in the analysis
should be clearly defined in terms of frequency, component
services (including services that may have preceded the in-
tervention and that would affect its course), dose or inten-
sity, duration, and any variations required for target sub-
groups.
II-3 Although data are an essential component of a model, the
conceptual structure of a model should be driven by the deci-
sion problem or research question and not determined by data
availability.
II-3a The choice of strategies/comparators crucially affects
results, and should be determined by the decision problem
and not by data availability or quality. All feasible and prac-
tical strategies should be considered. Constraining the
range of strategies should be justified.
II-3b The time horizon of the model should be long enough
to capture relevant differences in outcomes across strate-
gies. A lifetime horizon may be required.
II-4 The conceptual representation of the decision problem
should be used to identify key uncertainties in model structure
where sensitivity analyses could inform the impact of struc-
tural choices. For example, where a lifetime horizon is used,
the impact of alternative methods of extrapolating beyond the
observed data should be explored.
II-5 The policy context of the model should be clearly stated.
This includes who funded the model, who developed the
model, whether the model was developed for a single applica-
tion or multiple potential applications, and who the policy au-
dience for the modeling work is.
II-6 An explicit process (expert consultations, influence dia-
grams, concept mapping, or similar method) should be used to
convert the conceptualization of the problem into an appropri-
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theory of disease or the process being modeled.
II-7 There are often several types of models that are suitable for
the decision problem, and versions of each of the three model-
ing types in the series can be used for the same decision prob-
lem. Some problems are more naturally represented in certain
modeling types than in others.
II-7a For relatively simple models, or decision problems
with special characteristics (e.g. very short time horizons,
complex value structures) a decision tree may be appropri-
ate.
II-7b If the conceptualization involves representing the dis-
ease or treatment process as a series of health states, state-
transition models are often appropriate as they may be sim-
ple to develop, debug, communicate, analyze and readily
accommodate the evaluation of parameter uncertainty.
Their primary disadvantage, the Markovian assumption
that transition probabilities do not depend on past history,
can be addressed by increasing the number of states. Indi-
vidual-based state-transition models (termed “microsimu-
lations”), which do not require this assumption, are an al-
ternative when the number of states grows too large.
II-7c When the disease or treatment process includes inter-
actions between individuals, the modeling methods should
be able to represent and evaluate the effects of those inter-
actions (dynamic transmission models, discrete event sim-
ulations, agent-based models).
II-7d When the decision problem involves resource con-
straints, the modeling method should be able to represent
and evaluate the effects of those constraints (discrete event
simulation, agent-based models).
II-7e For some decision problems, combinations of model
types, hybrid models, and other modeling methodologies
are appropriate.
II-8 Model simplicity is desirable for transparency, ease of val-
idation and description. However, the model should be suffi-
ciently complex to answer the question at a level of detail con-
sistent with the problem being modeled, and to preserve face
validity to clinical experts. Greater complexity may be neces-
sary in policy models that are intended to be used for many
decision problems.
III. State-transition models
III-1 If the decision problem can be represented with a manage-
able number of health states that incorporate all characteris-
tics relevant to the decision problem, including the relevant
history, a cohort simulation should be chosen because of its
transparency, efficiency, ease of debugging, and ability to con-
duct specific value of information analyses. If, however, a valid
representation of any aspect of the decision problem would
lead to an unmanageable number of states, then an individual-
level state-transition model is recommended. Validity should
not be sacrificed for simplicity.
III-2 The strategies being evaluated should be clearly defined.
In particular, sequential decisions should not be modeled
within the Markov cycle tree but rather be part of the specifi-
cation of the alternative intervention strategies that precede
the Markov tree.
III-3 The starting cohort should be defined by the demographic
and clinical characteristics that affect the transition probabili-
ties or state values (e.g., quality of life and cost).
III-4 Specification of states and transitions should generally
reflect the biological/theoretical understanding of the disease
or condition being modeled.III-5 States should adequately capture the type of intervention
(i.e., prevention, screening, diagnostics, treatment) as well as
the intervention’s benefits and harms.
III-6 States need to be homogeneous with respect to both the
observed and unobserved (i.e., not known by the decision
maker) characteristics that affect transition probabilities.
III-7 The time horizon for the model should be sufficiently large
to capture all health effects and costs relevant to the decision
problem.
III-8 Cycle length should be short enough to represent the fre-
quency of clinical events and interventions.
III-9 Components of state-transition models that reflect similar
clinical courses should not be recreated but rather should be
incorporated once and linked to that structure throughout the
model.
III-10 Transition probabilities and intervention effects should
be derived from the most representative data sources for the
decision problem.
III-11 All methods and assumptions used to derive transition
probabilities and intervention effects should be described.
III-12 Parameters relating to the effectiveness of interventions
derived from observational studies should be correctly con-
trolled for confounding. Time-varying confounding is of partic-
ular concern in estimating intervention effects.
III-13 The valuation of intermediate outcomes/states should be
justified.
III-14 A half-cycle correction factor should be applied to both
costs and effectiveness and should be applied in the first cycle.
A half-cycle correction should also be applied in the final cycle
for analyses that do not use a lifetime horizon.
III-15 For certain decision problems, it may be important to
report not only the expected value but also the distribution of
the outcomes of interest.
III-16 The number of individuals modeled in an individual-
based simulation should be large enough to generate stable
estimates of the expected value of interest.
III-17 The report should use nontechnical language and clear
figures and tables that enhance the understanding of the
model to communicate its key structural elements, assump-
tions, and parameters.
III-18 In addition to final outcomes, intermediate outcomes
that enhance the understanding and transparency of the
model results should also be presented.
IV. Discrete event simulation (DES)
IV-1 Discrete event simulation (DES) models should be used
when the problem under study involves constrained or limited
resources. DES is also an attractive option in nonconstrained
models when there are interactions between individuals; pop-
ulations and/or their environment, when time-to-event is best
described stochastically rather than with fixed time intervals
and time dependencies are important; when individual path-
ways through the model are influenced by multiple character-
istics of the entity; and when recording individual entity expe-
rience is desirable.
IV-2 Constrained resource models should consider health-re-
lated outcomes, and not focus solely on measures of through-
put.
IV-3 The effects of constrained resources should be modeled if:
X evaluated technologies result in differing levels of access
(e.g. different referral rates), and
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on costs and/or outcomes (e.g. surgery).
IV-4 If downstream decisions can have significant effects on
the differences in costs and/or outcomes of the primary object
of an evaluation, the model should be structured to facilitate
analyses of alternative downstream decisions.
IV-5 Where there are competing risks of events, parameteriza-
tion approaches that represent correlation between the likeli-
hood of competing events are preferred to the specification of
separate time to event curves for each event.
IV-6 Where possible, progression of continuous disease param-
eters and the likelihood of related events should be defined
jointly to maintain the discrete event nature of DES, for exam-
ple, sample the level of the continuous measure (e.g. HbA1c
score) at which an event occurs, and then sample the time at
which the level is reached.
IV-7 To simplify debugging and updating, sub-models should
be used to structure the model. When comparing two or more
strategies within the same system (e.g. for the same condition
in a health technology assessment model), sub-models com-
mon to all strategies (e.g. progression following disease recur-
rence) should be defined once, and called from each strategy
(i.e. all patients experiencing a recurrence pass through the
common disease recurrence module).
IV-8 For structural sensitivity analyses, alternative structures
should be implemented within a single DES.
IV-9 Analysts should ensure that the mechanism for applying
ongoing risk(s) over multiple events remains active over the
relevant time horizon.
IV-10 Model implementation should account for the outputs
required for the validation and the final analyses of the model.
Where individual level data is required, relevant outputs
should be stored as attributes, otherwise aggregated values
should be collected from each model run to reduce the simu-
lation burden.
IV-11 The choice between using general programming or ded-
icated DES (“off-the-shelf”) software should be informed by the
relative importance of flexibility and execution speed (general
programming languages) vs. modeling efficiency, automated
structure and transparency (dedicated DES software). Spread-
sheet software is generally inappropriate for implementing
DES and should not be used without justification.
IV-12 When run times for probabilistic sensitivity analysis are
constrained, the optimal combination of run size (per input
parameter set) and numbers of alternative input parameter
sets tested should be estimated empirically to optimize the
precision of the outputs of interest.
IV-13 If the number of strategies to compare is large or there are
many structural assumptions to test, then “factorial design”
and optimum seeking approaches should be used.
IV-14 When computing time precludes adequate representa-
tion of uncertainty, meta-modeling (statistical representation
of the model input-output relationship) should be used.
IV-15 If the system to be modeled is not empty at the start of
the time horizon to be evaluated, a warm-up period should be
used build the system up to the starting point if:
X it can be reasonably assumed that the key parameters have
remained constant over time, or
X the history of the key parameters can be incorporated into
the warm-up period (e.g. the introduction of new health
technologies can be described).
IV-16 Animated representation of DES that displays the expe-
rience of events by individuals is recommended as a means ofengaging with users, as well to helping to debug the model
through the identification of illogical movements.
IV-17 Both general and detailed representations of a DES
model’s structure and logic should be reported to cover the
needs of alternative users of the model. Detailed event doc-
umentation figures are also of benefit to the analyst, as a
point of referral when returning to a model after a period of
absence.
V. Dynamic transmission models
V-1 A dynamic model is needed when a modeler is trying to
evaluate an intervention against an infectious disease that 1)
has an impact on disease transmission in the population of
interest, and/or 2) alters the frequency distribution of strains
(e.g., genotypes or serotypes).
V-2 The appropriate type of dynamic transmission model
should be used for the analysis in question, based in part on the
complexity of the interactions as well as the size of the popu-
lation of interest and the role of chance effects. This model
could be deterministic or stochastic, and population or individ-
ual-based. Justification for the model structure should be
given.
V-3 Conduct sensitivity analysis on the time horizon and dis-
count rate.
V-4 Conduct uncertainty analyses on known key structural as-
sumptions that may have an impact on the conclusions, or
justify the omission of such analyses.
V-5 When conducting sensitivity analyses, consideration of
important epidemic thresholds is helpful when there is a pos-
sibility of the model exhibiting alternate behaviors.
V-6 For differential equation-based models, adaptive time step
methods for numerical integration, that allow the degree of
error tolerance to be specified in advance, are preferred to
those that use a fixed time step of indeterminate accuracy.
V-7 If using a differential equations model, provide the model
equations. Tabulate all initial values and parameters, including
the mixing matrix and supply details of the type of mixing
considered.
V-8 If using an agent-based model, thoroughly describe the
rules governing the agents, the input parameter values, initial
conditions and all sub-models.
V-9 Show the transmission dynamics over time (e.g., incidence
and prevalence of infection and disease). When applicable, re-
port changes in other infection-specific outcomes such as
strain replacement and the emergence of resistance to antimi-
crobial drugs.
VI. Parameter estimation and uncertainty
VI-1 The systematic examination and reporting of uncertainty
are hallmarks of good modeling practice. All modeling studies
should therefore include an assessment of uncertainty as it
pertains to the decision problem being addressed.
VI-2 The role of the decision maker should be considered when
presenting uncertainty analyses. In particular, the description
of analytic perspective should include an explicit statement
regarding what is assumed about the power of the decision
makers to delay or review decisions and to commission or
mandate further research.
VI-3 Terminology to describe concepts relating to parameter
estimation and representation of uncertainty varies within the
medical decision modeling field and in comparison to related
fields. Authors should be aware of this and seek to carefully
define their use of terminology to avoid potential confusion.
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estimated. In populating models with parameter estimates,
analysts should conform to the broad principles of evidence-
based medicine. For example, analysts should: seek to identify
and incorporate all relevant evidence, rather than cherry pick-
ing the best single source of evidence for that parameter; use
best practice methods to avoid potential biases in parameter
estimates that might arise (for example, when estimating
treatment effectiveness from observational sources); and em-
ploy formal evidence syntheses techniques (meta analysis and
network meta analysis) as appropriate.
VI-5 Whether employing deterministic sensitivity analysis
methods (point estimate and range) or probabilistic sensitivity
analysis (parameterized distribution) the link to the underlying
evidence base should be clear.
VI-6 While completely arbitrary analyses, such as the presen-
tation of the effect on model outputs of varying each input
parameter by/ 50%, can be used as a measure of sensitivity,
such analyses should not be used to represent uncertainty.
VI-7 Analysts should give consideration to using commonly
adopted standards from statistics for point estimate and inter-
val estimation for input parameters, such as 95% confidence
intervals, or distributions based on agreed statistical methods
for a given estimation problem. Where departures from these
standards are deemed necessary (or where no such standard
exists for a given estimation problem), these should be justi-
fied.
VI-8 When there is very little information on a parameter, an-
alysts should adopt a conservative approach such that the ab-
sence of evidence is reflected in a very broad range of possible
estimates. On no account should parameters be excluded from
a sensitivity analysis on the grounds that ‘there is not enough
information from which to estimate uncertainty’.
VI-9 In choosing distributional forms for parameters in a prob-
abilistic sensitivity analysis, favor should be given to continu-
ous distributions that provide a realistic portrayal of uncer-
tainty over the theoretical range of the parameter of interest.
Hence careful consideration should be given to whether distri-
butions like the triangular should have any role in a probabi-
listic sensitivity analysis.
VI-10 Correlation among parameters should be considered.
Jointly estimated parameters, such as those from a regression
analysis, will have direct evidence on correlation which should
be reflected in the analysis. Independently estimated parame-
ters will have no such evidence, but this should not necessarily
lead to an assumption of independence. Possible approaches
are 1) to include a correlation coefficient as a parameter to the
model where concern exists that an unknown correlation be-
tween parameters could be important, or 2) to reparameterize
the model so that that the uncertain parameters can be reason-
ably assumed to be independent.
VI-11 Where uncertainties in structural assumptions were
identified in the process of conceptualizing and building a
model, those assumptions should be tested in a sensitivity
analysis. Consideration should be given to opportunities to pa-
rameterize these uncertainties for ease of testing. Where it is
not possible to perform structural sensitivity analysis it is nev-
ertheless important that analysts be aware of the potential for
this form of uncertainty to be at least as important as param-
eter uncertainty for the decision maker. (Linked to conceptual
modeling recommendations)
VI-12 Uncertainty analyses can be either deterministic or prob-
abilistic, and often it is appropriate to report aspects of both
types within a single evaluation. Tornado diagrams, threshold
plots, or simple statements of threshold parameter values, areall appropriate ways of reporting results from deterministic
sensitivity analyses.
VI-13 When additional assumptions or parameter values are
introduced for purposes of uncertainty analyses, such as dis-
tributional parameters for probabilistic sensitivity analyses, or
parameter ranges for deterministic sensitivity analyses, these
values should be disclosed and justified. Technical appendices
are often appropriate for this purpose.
VI-14 When model calibration is used to derive parameters,
uncertainty around the calibrated values should also be re-
ported, and this uncertainty should be reflected in either de-
terministic or probabilistic sensitivity analyses, or both.
VI-15 When the purpose of a probabilistic sensitivity analysis is
to guide decisions about acquisition of information to reduce
uncertainty, results should be presented in terms of expected
value of information.
VI-16 For economic studies, when a probabilistic sensitivity
analysis is performed without an accompanying expected
value of information analysis, options for presenting results
include cost-effectiveness acceptability curves (CEACs), and
distributions of net monetary benefit or net health benefit.
When more than two comparators are involved, CEACs for
each comparator should be plotted on the same graph.
VII. Transparency and validation
VII-1 Every model should have non-technical documentation
that is freely accessible to any interested reader. At a minimum
it should describe in non-technical terms the type of model and
intended applications; funding sources; structure of the model;
inputs, outputs, other components that determine the model’s
function, and their relationships; data sources; validation
methods and results; and limitations.
VII-2 Every model should have technical documentation, writ-
ten in sufficient detail to enable a reader with the necessary
expertise to evaluate the model and potentially reproduce it.
The technical documentation should be made available openly
or under agreements that protect intellectual property, at the
discretion of the modelers.
VII-3 Validation of a model should include an evaluation of face
validity of the structure, evidence, problem formulation, and
results of the model. A description of the process used to eval-
uate face validity should be made available on request. Evalu-
ation of face validity should be made by people who have ex-
pertise in the problem area, but are impartial to the results of
an analysis. If face validation raises questions about a model,
these issues should be discussed by the modelers in their re-
port of an analysis.
VII-4 Models should be subjected to rigorous verification. The
verification methods should be described in the non-technical
documentation of the model. The pertinent results of verifica-
tion should be made available on request.
VII-5 Modelers should search for previously published model-
ing analyses of the same or similar problems and discuss in-
sights gained from similarities and differences in results.
VII-6 Builders of models should have a formal process for con-
ducting external validation that includes:
X Systematic identification of suitable data sources; justifica-
tion of the selection; specification of whether a data source
is dependent, partially dependent, or independent; and de-
scription of which parts of the model are evaluated by each
data source.
X Simulation of each data source and comparison of results
X Quantitative measures of how well the model’s resultsmatch the outcomes observed in the data source
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X Data source
X Set up of the simulation
X Discrepancies between the data source and simulation
setup, and implications of the discrepancies
X Comparisons of simulation results with observed results
X Discussion of discrepancies between simulation results
and observed results
X Sensitivity analyses
VII-8 Modelers should make available on request a description
of the external validation process and results
VII-9 Modelers should identify parts of a model that cannot be
validated because of lack of suitable data sources, and describe
how uncertainty about those parts is addressed.
VII-10 For multi-application models, modelers should describe
criteria for determining when validations should be repeated
and/or expanded.
VII-11 When feasible with respect to the decision being ad-
dressed and the availability of a future data source, a model
should be tested for its prediction of future events. Builders of
multiple-use models should seek opportunities to conduct pre-
dictive validations as part of their overall validation process.
Quandaries
A major quandary in modeling is the choice of technique that will
be used to structure and analyze the model. Many techniques and
variations are available and, with sufficient effort and ingenuity,
most problems can be structured in any of the techniques [1]. This
does not mean that the techniques are interchangeable and that
the choice should be made casually. With advances in computing
that render massive calculations quite feasible, it is expected that
there will be increasing use of individual-based simulations be-
cause the computational challenges of simultaneously addressing
stochastic uncertainty and parameter uncertainty in probabilistic
sensitivity analysis diminish. Individual-based simulations are
less subject to limitations imposed by the cohort simulation ap-
proach, particularly with regard to patient history based on events
experienced within the model. Whether to frame them in terms of
states or events will be of lesser concern. Indeed, there is no reason
to treat these as mutually exclusive alternatives: hybrid models
with some components represented as states and others as events
are readily constructed and can be a very flexible and accurate
approach with no restrictions in terms of how time is handled. At
the same time, overly complex models should be avoided if a sim-
pler one will accurately reflect all aspects of the decision problem.
Another quandary is whether to allow the design of a model to
be driven by the data at hand. The idea that this should not be the
case—detailed in the conceptualization article [1]—may rankle
some on the grounds that there is not much point in designing a
detailed model that can then not be populated by existing data.
While a model lacking information on many inputs is not very
useful, the reasons for designing first and looking at data after are
that this produces more appropriate, relevant designs and often
leads to looking for, and finding, data that might otherwise have
been overlooked. The choice of data and their processing to yield
suitable inputs for the model is a vast topic covered in other fields
such as epidemiology. While this series does not address this in
any detail, it is emphasized that good practice of evidence-based
medicine should be followed. Whatever choices are made, the
model parameters should reflect the uncertainty over the data
gaps [5], which will ensure that a value of information analysis will
provide the necessary impetus to launch studies to obtain the
necessary data.The converse situation is also of note: just because detailed
data exist is not a sufficient reason to build a very complex model.
The art of building models rests on the principle of parsimony, or
Occam’s Razor. We do not suggest that finding the balance be-
tween simplicity of modeling and avoidance of oversimplification
is easy, but it is perhaps the most important skill a modeler can
learn if a model is to truly fulfill its potential as a communication
tool. Excessive detail and complexity reduce transparency and can
lead to distrust in models and in the modeling community among
those we seek to inform.
Throughout the series of articles, the subject of structural un-
certainty keeps cropping up. This is a particularly difficult quan-
dary [27]. There is no doubt that the choices made in structuring
the model can significantly affect the results, and thus inferences
made from them. In many cases, those choices are made on the
basis of expert opinion, or influenced by concerns for simplicity,
feasibility of implementation, and so on. This process leaves much
room for uncertainty, but it is very difficult to quantify and analyze
this uncertainty. This hurdle is augmented by using software spe-
cific for simulation not designed for modeling—many of those that
are used include features that facilitate structural sensitivity anal-
ysis. In principle, all the alternatives considered could be modeled
and the impact on the results examined. The effort involved tends
to be perceived as prohibitive though, and even if the investment
were made, the universe of possibilities is vast and extends be-
yond what the individual modeler might consider. Clearly, struc-
tural uncertainty is a topic ripe for intensive research. It is hoped
that the next edition of the guidelines will be able to provide firm
recommendations in this regard.
Another quandary arises in the article on uncertainty, in which
it is stated that arbitrary ranges should not be used when exam-
ining the impact of uncertainty on the results. The reason is that
such an analysis reveals how sensitive the model is to changes in
that input but does not address uncertainty since the range of
values is not a reflection of the latter. This poses a practical di-
lemma for modelers: how to address uncertainty when it is clear
that an input is not exact but it is not clear to what degree. One
could argue that the solution is to collect data on that input and
use that process to quantify the uncertainty. This will usually not
be feasible in a timely way, however. Thus, an option would be to
employ Bayesian methods to create a probability distribution
around the estimate and use this to quantify the relevant uncer-
tainty. Given the practical and methodological difficulties, this
area should be a focus of research.
Often, when reporting the results of a model analysis, the term
“robust” is used. This term may be misinterpreted to mean that
the results are unaffected by changes to the inputs, whereas it
should indicate that within the uncertainty of the inputs, the con-
clusions (i.e., suggested decisions) were not altered. It would be
quite worrisome if a model did not react to changes in its inputs;
were this to be the case, one would conclude that there must be a
major problem with the model as a proper one should respond to
changes in inputs. Also, this is not a property of a model but rather
of a particular analysis and set of results. Robustness is not per se
a desirable feature. Instead, what investigators should examine
are the conditions that alter the implications for the decision at
issue and their credibility.
A particularly difficult quandary tackled by the Task Force is
the conflict between the scientific desirability of making all meth-
odological and technical details of a model available to peer re-
viewers and to other researchers and the need to protect intellec-
tual property generated by substantial investments in the
development of a model. As rejecting the latter would significantly
reduce the incentive to devote major efforts to creating models—
particularly those intended for multiple uses—the Task Force
agreed, reluctantly, to recommend that intellectual property not
be ignored. Instead, the proposal is to ask that modelers make full
[[
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they feel are necessary to grant them adequate protection. This
should allow for detailed review of any model by other scientists,
provided they are willing to abide by the confidentiality restric-
tions.
A final quandary is that models are often created in our field to
address decisions regarding the use of limited resources but the
modelers typically ignore the actual short-term resource con-
straints. Despite the availability of methods to simulate those con-
straints, most models regularly assume that any resource that is
needed is immediately available and consumed, regardless of ac-
tual supply (or likely demand). Thus, the vexing health care
queues common in many countries are not incorporated, nor are
changes in waiting times as a consequence of new interventions.
The potential for helping health systems adapt to changing prac-
tices in the short term has been overlooked. Incorporating this
aspect would, undoubtedly, add another layer of complexity to
models and a further demand for data that might be difficult to
obtain, but it is a gap in current practice. Perhaps by the time the
next guidelines are developed, our field will have advanced to as-
sist decision makers not only with the challenge of which inter-
ventions to adopt but also with that of handling the implementa-
tion of system changes more efficiently.
Conclusion
The recommendations for best practices provided in this article
and detailed in the accompanying six articles are intended, in the
first instance, for practitioners who build models. Nevertheless,
they should be of use to the decision makers who are the audience
for the models’ results, as well as those who commission models,
granting agencies that fund them, and even those who report on
the results and their implications.
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